- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00736541
N-acetylcysteine in Liver Transplantation (NAC)
Investigation of the Efficacy of N-acetylcysteine (NAC) to Protect Against Hepato-renal Ischemia-reperfusion Injury in Patients Undergoing Orthotopic Liver Transplantation
N-acetylcysteine (NAC) is used to treat Tylenol toxicity. NAC is a rich source of the sulfhydryl group (SH) which is important for replenishing the body's glutathione stores. Glutathione acts as a free radical scavenger, to decrease the damage that would be caused by those toxic radicals. Patients who undergo orthotopic liver transplantation (OLT) have a high incidence of post-operative renal dysfunction. The most common etiology of post-operative renal dysfunction is related to high levels of toxic free radicals. Free radicals may contribute to primary liver graft failure or delayed liver graft function.
Specific Aims & Objectives:
The primary objective of this study is to evaluate the efficacy of NAC in improving liver graft performance and lowering the incidence of post-operative renal dysfunction. The secondary objectives are to investigate the effect of NAC on endogenous glutathione body stores and its effect on FK506 induced toxicity.
Study Overview
Detailed Description
This is a randomized, double-blind placebo-controlled study that investigates the use of NAC during and after OLT. A total of 100 patients will be recruited. Fifty will receive a placebo (normal saline) and the other fifty will receive NAC. The patients in the NAC group will receive a loading dose of 140 mg/kg IV of NAC over one hour at the start of the surgery. Thereafter, NAC will be repeated every 4 hours at a dose of 70 mg/kg IV, for a total of 13 doses. The placebo group will receive an equal volume of a normal saline infusion for 13 doses. Both groups will be followed for one year after their OLT. The following data will be recorded and collected: liver function tests, renal function tests, liver graft survival rate, patient survival, serum level of glutathione (GSH-PX/GR), duration of hospital and ICU stay. To evaluate the accuracy of calculated serum creatinine clearance (CSCC) in predicating the renal performance in OLT patients, another two serum markers will be estimated. The 1st one is Cystatin-C and the 2nd is Beta-trace. The data from CSCC, cystatin-C and beta-trace will be compared to find out which is the best marker in between these three tests to predicate the renal function. The data will be recorded daily for the first week after the surgery, then on days 14, 21, 30, 90, 180 and finely at the end of the first year after the OLT. Statistical analysis of the data will be performed at the conclusion of the study period to determine the difference in the outcome and morbidity and mortality between the two groups.
Objective and Specific Aims
Objectives:
- Assess the efficacy of NAC to preserve liver graft function and to improve patient/graft survival following orthotopic liver transplantation.
- Assess the efficacy of NAC to preserve kidney function in the patients undergoing OLT.
Primary Aims:
- Severity of the post reperfusion syndrome (PRS) will be compared in both groups by assessing hemodynamic parameters and the need for vasopressor support in the neohepatic stage.
- Liver graft function, the incidence of primary non-function and delayed function in both the treatment and placebo groups, will be assessed with post-operative liver function tests (ALT, AST, serum bilirubin, PT/INR, APTT, lactate, etc). Liver function tests will be assessed at one month, three month, six month and at one year following the OLT.
- The duration of ICU and hospital stays will be compared between the two groups.
- Survival rate (patient/graft) between the treatment and placebo groups will be compared at 1 month, 3 months, 6 months and 1 year.
- Renal function will be compared in the treatment and placebo groups by assessing the following parameters during and after liver transplantation: urine output (ml/24 hours), serum creatinine and BUN, calculated creatinine clearance.
- The incidence of postoperative acute renal failure (ARF) and the extent and duration of renal dysfunction will be compared between the treatment and the placebo groups.
Secondary Aims:
- Investigating the effect of NAC on the endogenous glutathione peroxides/glutathione reductase (GSH-PX/GR) body stores in patients undergoing OLT.
- Investigating the effect of NAC on FK506 induced toxicity.
- Investigating the accuracy of two new markers for evaluating the renal function and glomerular filtration rate and compare them to CSCC.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Unversity of Pittsburgh Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patients age of 18 years
- Patients undergoing cadaveric liver transplant for the first time
- Patients with normal serum creatinine < 1- 1.2 mg/dl or creatinine clearance 97-140 ml/min and patients with mild renal dysfunction with serum creatinine of (2-2.5 mg/dl) or creatinine clearance 85-125 ml/min
- All patients will sign informed consent
Exclusion Criteria:
- Allergy to NAC
- Patients with history of asthma
- Patient with fulminate hepatic failure
- Re-do OLT
- Simultaneous other organ transplant (i.e., pancreas, heart, and small bowel)
- Pre-existing renal failure requiring hemodialysis or continuous hemofiltration and patient refusal to participate in the study.
- Although, it is extremely uncommon for a patient with hepatic failure to become pregnant due to the pathological effect of hepatic failure on the reproductive system, the policy of Liver Transplantation Service at UPMC is to advise young female not to become pregnant while waiting for OLT. In addition the majority of the patients on the liver transplant waiting list at this institution are above 50 years of age. However, when a female patient of child-bearing potential is called in for OLT and there is a suspicion that she might be pregnant, a blood pregnancy test will be performed as a part of the standard of care for these patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2
|
The patients in the NAC group will receive a loading dose of 140 mg/kg IV of NAC over one hour at the start of the surgery.
Thereafter, NAC will be repeated every 4 hours at a dose of 70 mg/kg IV, for a total of 13 doses
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
improve patient and graft outcome. reduce the incidence of postoperative renal dysfunction
Time Frame: one year
|
one year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ibtesam A Hilmi, MB CHB, FRCA, University of Pittsburgh Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Hepatic Insufficiency
- Liver Diseases
- Liver Failure
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Protective Agents
- Respiratory System Agents
- Antioxidants
- Antidotes
- Free Radical Scavengers
- Expectorants
- Cysteine Proteinase Inhibitors
- Acetylcysteine
- N-monoacetylcystine
- Cystatins
Other Study ID Numbers
- N-acetylcysteine in OLT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Liver Failure
-
Vanderbilt University Medical CenterEnrolling by invitationEnd Stage Liver DIseaseUnited States
-
Virginia Commonwealth UniversityCompletedEnd Stage Liver DIseaseUnited States
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonCompletedEnd-stage Liver DiseaseUnited Kingdom
-
Proteonomix, Inc.University of Medicine and Dentistry of New Jersey; NumodaUnknownEnd Stage Liver DIseaseUnited States
-
University of ZurichUniversity Ghent; University Hospital of Sao Paulo, BrazilCompleted
-
RenJi HospitalNot yet recruitingEnd Stage Liver DIsease
-
Mayo ClinicRecruiting
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Huashan HospitalRecruiting
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
Clinical Trials on N-acetylcysteine
-
Medical University of South CarolinaCompleted
-
Institut d'Anesthesiologie des Alpes MaritimesCompleted
-
Rajavithi HospitalCompletedChemotherapy-induced Peripheral NeuropathyThailand
-
University of Sao Paulo General HospitalActive, not recruiting
-
Indiana UniversityBioAdvantex PharmaCompletedHIV | Endothelial Dysfunction | Oxidative StressUnited States
-
Assaf-Harofeh Medical CenterUnknownChronic Kidney Diseases | General AnesthesiaIsrael
-
Assistance Publique - Hôpitaux de ParisTerminatedSelenoprotein N-related MyopathyFrance
-
VA Office of Research and DevelopmentNational Center for Complementary and Integrative Health (NCCIH)CompletedDiabetic Nephropathy | Proteinuria | Oxidative StressUnited States
-
University of ChicagoNational Institute on Drug Abuse (NIDA); University of MinnesotaCompletedTobacco Use Disorder | GamblingUnited States
-
Universidade Estadual de LondrinaUnknownInflammation | Tobacco Smoking | Oxidative StressBrazil